※一部利用できない機能があります
| 1.
論文（リポジトリ） |
論文（リポジトリ）
|
Nakasone, Hiroki ; Sakugawa, Hiroshi ; Shokita, Hayashi ; Arakaki, Noriko ; Kudeken, Norifumi ; Toyoda, Kazumasa ; Nakayoshi, Tomofumi ; Kawakami, Yuko ; Kinjo, Fukunori ; Saito, Atsushi ; Wakuta, Moriaki ; Uehara, Takeshi
概要:
Fulminant hepatic failure (FHF) is known to have a poor prognosis, particularly in patients with a more gradual onset of
…
hepatic encephalopathy (called subacute type). The presence of coagulopathy and the grade of hepatic coma are associated with a worsened prognosis. A 47 year-old woman with subacute type FHF was treated with a combination therapy of plasma exchange and hemodiafiltration, using a high-performance polymethyl metacrylate membrane. After this treatment, she regained consciousness and was stable in the lower hepatic coma grade for a long period (294 days). This survival period was longer than those of 340 patients with FHF who were treated with PE alone, and eventually died of FHF between 1983 and 1988 in Japan.
論文 続きを見る |
||||
| 2.
論文（リポジトリ） |
論文（リポジトリ）
|
佐久川, 廣 ; 仲宗根, 啓樹 ; 仲吉, 朝史 ; 川上, 祐子 ; 諸喜田, 林 ; 新村, 政昇 ; 照屋, 寛 ; 前原, 信人 ; 金城, 渚 ; 外間, 昭 ; 大城, 淳一 ; 金城, 福則 ; 斎藤, 厚 ; 山城, 章裕 ; 上地, 博之 ; 親泊, 康朝 ; 石原, 昌清 ; 嘉手納, 啓三 ; 大湾, 朝二 ; 宮平, 守博 ; 池間, 稔 ; 仲吉, 朝邦 ; 与儀, 裕 ; 小波津, 寛 ; 中村, 博 ; 城間, 健治 ; 比嘉, 昌文 ; 平山, 良克 ; 上原, 剛 ; Sakugawa, Hiroshi ; Nakasone, Hiroki ; Nakayoshi, Tomofumi ; Kawakami, Yuko ; Shokita, Hayashi ; Niimura, Seisho ; Teruya, Hiroshi ; Maehara, Nobuto ; Kinjo, Nagisa ; Hokama, Akira ; Ohshiro, Junichi ; Kinjo, Fukunori ; Saito, Atsushi ; Yamashiro, Akihiro ; Uechi, Hiroyuki ; Oyadomari, Yasutomo ; Ishihara, Masakiyo ; Kadena, Keizo ; Ohwan, Choji ; Miyahira, Morihiro ; Ikema, Minoru ; Nakayoshi, Tomokuni ; Yogi, Yutaka ; Kohatsu, Hiroshi ; Nakamura, Hiroshi ; Shiroma, Kenji ; Higa, Masafumi ; Hirayama, Yoshikatsu ; Uehara, Takeshi
概要:
Five different dosage regimens of recombinant interferon ($ \gamma $IFN) alfa-2 b were compared in patients with chronic
…
hepatitis C. Ninety-four patients were assigned to one of five groups: group 1, 2 and 3 were given 3, 6 and 10 million units (MU) , respectively, of $ \gamma $IFN alfa-2b daily for 2 weeks, followed by thrice weekly for 22 weeks (total dose: 240, 480 and 800 MU) , respectively. Group 4 and 5 were given 10 MU of $ \gamma $IFN alfa-2b daily for 2 weeks, followed by 10 MU thrice weekly for 12 weeks (group 4) or 6 MU thrice weekly for 22 weeks (group 5), with a total dose of480 and 536 MU, respectively. Sustained response to $ \gamma $IFN was seen in 7.7% (1/13) of patients in group 1. The rate was significantly lower than that of either group 2 or 3 (p<0. 05 in each comparison). There was no difference in the sustained response rate between group 2 and 3 (38.0%vs 44.0%). Comparison of the efficacy of group 4 or 5 with those of the other groups was not appropriate because of the small number of patients assigned in group 4 or 5. When the sustained response rate of patients infected with genotype 1b, which was known to be resistent to IFN treatment, is compared between group 2 and 3, higher response rate was seen in group 3 (26.3% in group 2 vs 42.1% in group 3), although not significantly.
論文 続きを見る |
||||
| 3.
論文（リポジトリ） |
論文（リポジトリ）
|
Nakasone, Hiroki ; Sgkuawa, Hiroshi ; Nakayoshi, Tmofumi ; Kawakami, Yuko ; Kinjo, Fukunori ; Saito, Atushi ; Yamashiro, Akiko ; Nakayoshi, Tmokuni ; Ikema, Minoru ; Hirayama, Yoshikatsu
概要:
The present study examined the efficacy and the predicting factors of response to interferon (IFN) alpha in patients wit
…
h liver cirrhosis associated with hepatitis type C virus infection (LC type C). Sixty-seven patients were treated with IFN alpha and were classified into 2 Groups. Group 1 : Patients with liver cirrhosis, showing histological liver cirrhosis or chronic active hepatitis with lobular disorganization. Group 2 : Patients with chronic hepatitis, showing histological chronic persistent hepatitis or chronic active hepatitis without lobular disorganization. Sustained response to IFN was obtained in 5/17 (29.4%) and 24/50 (48%) of patients in Group 1 and Group 2, respectively. However, the difference was not significant. All patients in Group 2 showed a significant decrease in alanine aminotransferase (ALT) levels during the treatment, whereas 5 of the 17 patients in Group 1 showed no response. All sustained responders in Group 1 who were tested for serum HCV-RNA titer showed low serum HCV-RNA titer, which was less than 10^7 copies/ml, while all except one patient of the non-responders of Group 1 showed above 10^8 copies/ml. It is said that patients with LC type C are more resistant to IFN treatment compared to those with chronic hepatitis type C. However, our findings suggest that even in patients with LC type C, low serum HCV-RNA levels might be associated with better response to IFN.
論文 続きを見る |
||||
| 4.
論文（リポジトリ） |
論文（リポジトリ）
|
Sakugawa, Hiroshi ; Nakasone, Hiroki ; Kawakami, Yuko ; Nakayoshi, Tomofumi ; Kinjo, Fukunori ; Saito, Atsushi ; Ikema, Minoru ; Yamashiro, Akihiro ; Nakayoshi, Tomokuni
概要:
To compare the clinical utility of type IV collagen 7S domain and hyaluronate, as markers in the evaluation of liver fib
…
rosis, 184 patients with biopsy-proven chronic viral liver disease (32; type B, 152; type C) were involved in this study. The two markers correlated well with the grade of liver fibrosis. The correlation coefficients of 7S-collagen and hyaluronate with the extent of fibrosis were 0.747 and 0.813, respectively. Very high values were seen more frequently in hyaluronate than in 7S-collagen, particularly in patients with moderate and severe fibrosis. Both markers also correlated strongly with conventional liver function tests except for alanine aminotransferase. In conclusion, serum hyaluronate was a more sensitive marker and seemed to more strongly correlate with the degree of hepatic fibrosis than type IV collagen 7S domain.
論文 続きを見る |
